← Leaderboards
Lacy M. Alexander
Pennsylvania State University, The
$6,341,929
Attributed
$8,019,769
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $882.3K · FY2009–25$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,019,769 · 4
By mechanism
R01$7,568,419 · 2
R21$405,350 · 1
R13$46,000 · 1
Top collaborators
- Nina Stachenfeld9 shared
- David N Proctor1 shared
Most similar at Pennsylvania State University, The
Same institution · by research overlap
- Nina Stachenfeld$8,907,589
Others in their field
Top investigators on “Vasodilation”
- Jonathan H Jaggar · University Of Tennessee Health Sci Ctr$16,366,261
- Claudia R Morris · Children'S Hospital &Res Ctr At Oakland$12,637,198
- William Bryson Campbell · Medical College Of Wisconsin$12,032,862
- Nabil J. Alkayed · Johns Hopkins University$11,563,230
- Noyan Gokce · Boston Medical Center$11,131,138
- Alejandro M Dopico · University Of Tennessee Health Sci Ctr$10,559,053
Research focus
VasodilationBlood VesselsSignal TransductionProductionInflammationMediatingImpairmentIn VivoVascular DiseasesInflammatoryNitric OxidePhysiologicalTherapeutic TargetOxidantsWomanCardiovascular DiseasesEndotheliumCardiovascular SystemMetabolismTherapeutic InterventionSiteCardiovascular Disorder RiskChronicPeripheral
Grant awards (21)
Mechanisms and interventions addressing accelerated cardiovascular disease risk in women with endometriosis$748,418
R01 · FY2025 · HL · contact PI
Mechanisms and interventions addressing accelerated cardiovascular disease risk in women with endometriosis$87,918
R01 · FY2025 · HL · contact PI
From Human Performance to Precision Health in an Aging World: Noll Lab at 50$46,000
R13 · FY2025 · AG
Mechanisms and interventions addressing accelerated cardiovascular disease risk in women with endometriosis$744,209
R01 · FY2024 · HL · contact PI
Mechanisms and interventions addressing accelerated cardiovascular disease risk in women with endometriosis$87,918
R01 · FY2024 · HL · contact PI
Mechanisms and interventions addressing accelerated cardiovascular disease risk in women with endometriosis$766,761
R01 · FY2023 · HL · contact PI
Mechanisms and interventions addressing accelerated cardiovascular disease risk in women with endometriosis$37,168
R01 · FY2023 · HL · contact PI
Mechanisms and interventions addressing accelerated cardiovascular disease risk in women with endometriosis$36,505
R01 · FY2023 · HL · contact PI
Mechanisms and interventions addressing accelerated cardiovascular disease risk in women with endometriosis$784,116
R01 · FY2022 · HL · contact PI
Mechanisms and interventions addressing accelerated cardiovascular disease risk in women with endometriosis$16,667
R01 · FY2022 · HL · contact PI
Essential Hypertension and Human Skin Blood Flow$605,270
R01 · FY2018 · HL · contact PI
Essential Hypertension and Human Skin Blood Flow$617,422
R01 · FY2017 · HL · contact PI
Essential Hypertension and Human Skin Blood Flow$609,827
R01 · FY2016 · HL · contact PI
Essential Hypertension and Human Skin Blood Flow$628,878
R01 · FY2015 · HL · contact PI
Essential Hypertension & Human Skin Blood Flow$349,298
R01 · FY2014 · HL · contact PI
Essential Hypertension and Human Skin Blood Flow$340,172
R01 · FY2013 · HL · contact PI
Essential Hypertension and Human Skin Blood Flow$342,357
R01 · FY2012 · HL · contact PI
Low-dose Aspirin and Human Skin Blood Flow$184,250
R21 · FY2011 · HL · contact PI
Essential Hypertension and Human Skin Blood Flow$383,674
R01 · FY2010 · HL · contact PI
Low-dose Aspirin and Human Skin Blood Flow$221,100
R21 · FY2010 · HL · contact PI
Essential Hypertension and Human Skin Blood Flow$381,841
R01 · FY2009 · HL · contact PI